Zisong Zhou
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial.
Journal: EClinicalMedicine
Published: January 25, 2025
Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis.
Journal: Hematological oncology
Published: November 23, 2024
Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
Journal: British journal of haematology
Published: September 14, 2024
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study.
Journal: Cytotherapy
Published: July 01, 2022
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.
Journal: American journal of hematology
Published: June 17, 2022
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.
Journal: Cancer medicine
Published: September 28, 2020
CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients.
Journal: Genes
Published: October 12, 2019
Showing 1-9 of 9
Last Updated: 09/26/2026